R&D News | pharmaphorum

News

Novartis agrees $5.7bn degrader deal with Monte Rosa

Novartis has signed its second multibillion-dollar licensing deal with molecular glue degrader specialist Monte Rosa in less than a year.

News

High dose of Wegovy drives weight loss to 19%

A triple dose of Novo Nordisk's GLP-1 agonist Wegovy has shown improved activity on weight loss in an obesity trial versus the current formulation.

News

AZ halts UK investment, and Lilly, Sanofi follow suit

After MSD's bombshell retreat from a big UK investment plan, AstraZeneca, Lilly, and Sanofi are also pressing pause on new projects.

News

Reaction to MSD's UK exit as government tries to renew talks

The UK government is reported to be trying to restart talks over drug pricing and rebates after MSD's shock decision to scrap a £1bn investment spend.

News

Pharma says UK is 'tumbling down' rankings for investment

The UK is losing out to competitors in attracting investment in R&D, clinical trials, and capital projects, says a report from the ABPI pharma group.

News

Fresh blow to UK life sciences as MSD abandons £1bn project

In a blow to UK life science ambitions, MSD has scrapped a £1bn expansion of its operations in the country, saying it does not value innovation.

Novartis agrees $5.7bn degrader deal with Monte Rosa

High dose of Wegovy drives weight loss to 19%

AZ halts UK investment, and Lilly, Sanofi follow suit

Reaction to MSD's UK exit as government tries to renew talks

Pharma says UK is 'tumbling down' rankings for investment

Fresh blow to UK life sciences as MSD abandons £1bn project

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks